Skip to main content
. Author manuscript; available in PMC: 2009 Jul 1.
Published in final edited form as: Diabetes Care. 2008 Mar 28;31(7):1367–1372. doi: 10.2337/dc07-2413

Online Appendix Table 2.

Sex-adjusted rates of hypertension, elevated levels of low lipoprotein cholesterol, type 2 diabetes, treatment and control among BMI categories, stratified by age

% of Participants (95% CI)

BMI 18.5-<25 BMI 25-<30 BMI ≥30 p-value*

N=1548 N=1327 N=828

<50 year Hypertension
  Prevalence 4.7 (3.7–5.9) 12.3 (10.4–14.3) 27.4 (23.9–31.2) <0.001
  Treatment 40.5 (25.6–56.7) 43.3 (33.3–53.8) 45.9 (36.9–55.2) 0.26
  Control 28.6 (16.6–43.3) 33.9 (25.4–43.2) 30.8 (23.8–38.6) 0.99

Elevated LDL-C
  Prevalence 6.0 (4.9–7.4) 17.0 (14.8–19.3) 24.3 (21.0–28.0) <0.001
  Treatment 23.2 (13.9–34.9) 36.4 (29.0–44.2) 30.6 (23.2–39.8) 0.48
  Control 18.4 (10.5–29.0) 29.1 (22.5–36.3) 25.5 (18.9–33.0) 0.34

Diabetes
  Prevalence 1.4 (0.8–2.2) 5.6 (4.1–7.5) <0.001
  Treatment 50.0 (11.8–88.2) 39.3 (21.5–59.4) 0.006
  FPG <126 mg/dL 36.4 (10.9–69.2) 15.4 (5.9–30.5) 0.02

50+ year N=910 N=1269 N=919

Hypertension
  Prevalence 26.2 (22.9–29.8) 39.7 (36.1–43.4) 54.1 (49.0–59.1) <0.001
  Treatment 67.4 (56.8–76.8) 67.5 (59.7–74.6) 74.1 (66.0–81.2) 0.006
  Control 37.9 (30.5–45.6) 37.8 (32.5–43.3) 42.5 (36.9–48.3) 0.69

Elevated LDL-C
  Prevalence 27.6 (24.1–31.2) 45.7 (41.9–49.5) 51.5 (46.5–56.4) <0.001
  Treatment 38.5 (31.1–46.2) 36.1 (31.2–41.3) 44.0 (38.1–50.0) 0.03
  Control 29.7 (23.3–36.7) 24.5 (20.5–28.8) 30.6 (25.7–35.7) 0.18

Diabetes
  Prevalence 3.2 (2.1–4.6) 7.2 (5.8–8.8) 18.4 (15.7–21.4) <0.001
  Treatment 61.5 (31.6–86.1) 48.8 (32.9–64.9) 58.9 (46.8–70.3) 0.43
  FPG <126 mg/dL 27.3 (10.7–50.2) 17.3 (9.6–28.2) 15.8 (10.3–22.7) 0.26

Abbreviations: CI, confidence interval; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; Hb A1c, Hemoglobin A1c level; FPG, fasting plasma glucose

SI conversion factor: To convert fasting plasma glucose to mmol/L, multiply mg/dL values by 0.0555

*

Global GEE p-value

Among participants younger than 50 years of age with a BMI 18.5-<25, there were only 5 individuals with diabetes mellitus. Of those, 5 received hypoglycemic treatment and 3 had FPG <126 mg/dL

Interpret p-value with caution as there are only small number in the cells of participants younger than 50 years of age with a BMI 18.5-<25